Skye Bioscience (SKYE) Competitors $3.45 -0.10 (-2.70%) As of 12:37 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SKYE vs. GOSS, ERAS, CMPX, KMDA, PVLA, RGNX, TECX, KOD, FULC, and CMPSShould you be buying Skye Bioscience stock or one of its competitors? The main competitors of Skye Bioscience include Gossamer Bio (GOSS), Erasca (ERAS), Compass Therapeutics (CMPX), Kamada (KMDA), Palvella Therapeutics (PVLA), REGENXBIO (RGNX), Tectonic Therapeutic (TECX), Kodiak Sciences (KOD), Fulcrum Therapeutics (FULC), and COMPASS Pathways (CMPS). These companies are all part of the "pharmaceutical products" industry. Skye Bioscience vs. Its Competitors Gossamer Bio Erasca Compass Therapeutics Kamada Palvella Therapeutics REGENXBIO Tectonic Therapeutic Kodiak Sciences Fulcrum Therapeutics COMPASS Pathways Skye Bioscience (NASDAQ:SKYE) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends. Is SKYE or GOSS more profitable? Skye Bioscience has a net margin of 0.00% compared to Gossamer Bio's net margin of -344.81%. Skye Bioscience's return on equity of -53.92% beat Gossamer Bio's return on equity.Company Net Margins Return on Equity Return on Assets Skye BioscienceN/A -53.92% -48.58% Gossamer Bio -344.81%-1,774.72%-46.73% Do analysts prefer SKYE or GOSS? Skye Bioscience presently has a consensus target price of $16.60, suggesting a potential upside of 380.60%. Gossamer Bio has a consensus target price of $8.50, suggesting a potential upside of 384.33%. Given Gossamer Bio's higher probable upside, analysts clearly believe Gossamer Bio is more favorable than Skye Bioscience.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Skye Bioscience 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Gossamer Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders have more ownership in SKYE or GOSS? 21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are held by institutional investors. 4.5% of Skye Bioscience shares are held by company insiders. Comparatively, 6.7% of Gossamer Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has more risk & volatility, SKYE or GOSS? Skye Bioscience has a beta of 2.21, indicating that its share price is 121% more volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.96, indicating that its share price is 96% more volatile than the S&P 500. Does the media prefer SKYE or GOSS? In the previous week, Gossamer Bio had 9 more articles in the media than Skye Bioscience. MarketBeat recorded 13 mentions for Gossamer Bio and 4 mentions for Skye Bioscience. Gossamer Bio's average media sentiment score of 0.63 beat Skye Bioscience's score of -0.56 indicating that Gossamer Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Skye Bioscience 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Gossamer Bio 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Which has preferable valuation & earnings, SKYE or GOSS? Skye Bioscience has higher earnings, but lower revenue than Gossamer Bio. Skye Bioscience is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSkye BioscienceN/AN/A-$26.57M-$0.82-4.21Gossamer Bio$114.70M3.48-$56.53M-$0.62-2.83 SummaryGossamer Bio beats Skye Bioscience on 9 of the 14 factors compared between the two stocks. Get Skye Bioscience News Delivered to You Automatically Sign up to receive the latest news and ratings for SKYE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SKYE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SKYE vs. The Competition Export to ExcelMetricSkye BioscienceMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$107.14M$2.98B$5.45B$9.65BDividend YieldN/A2.46%3.99%4.14%P/E Ratio-4.2218.0129.9924.99Price / SalesN/A174.97375.7976.03Price / CashN/A41.8335.9458.58Price / Book1.547.238.125.66Net Income-$26.57M-$54.43M$3.25B$265.39M7 Day Performance1.29%0.07%0.96%2.45%1 Month Performance-20.60%5.31%2.71%1.81%1 Year Performance-30.78%10.29%28.13%24.02% Skye Bioscience Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SKYESkye Bioscience1.4576 of 5 stars$3.45-2.7%$16.60+380.6%-31.2%$107.14MN/A-4.2211News CoverageEarnings ReportGOSSGossamer Bio3.9255 of 5 stars$1.96-1.0%$8.25+320.9%+114.3%$445.51M$124.59M-8.52180News CoveragePositive NewsEarnings ReportUpcoming EarningsAnalyst ForecastAnalyst RevisionHigh Trading VolumeERASErasca2.4613 of 5 stars$1.55-8.8%$4.57+194.9%-39.4%$439.10MN/A-2.50120Positive NewsUpcoming EarningsCMPXCompass Therapeutics2.9124 of 5 stars$3.17-0.9%$12.67+299.6%+208.9%$438.35M$850K-7.7320News CoverageUpcoming EarningsKMDAKamada4.5902 of 5 stars$7.51-2.2%$13.00+73.1%+33.5%$431.90M$160.95M25.90360News CoveragePositive NewsUpcoming EarningsPVLAPalvella Therapeutics2.696 of 5 stars$38.88-2.5%$47.50+22.2%N/A$429.86MN/A-3.21N/ANews CoverageUpcoming EarningsAnalyst ForecastAnalyst RevisionHigh Trading VolumeRGNXREGENXBIO3.9652 of 5 stars$8.41-4.3%$31.63+276.0%-34.4%$421.85M$83.33M-2.70370News CoverageEarnings ReportAnalyst ForecastTECXTectonic Therapeutic2.5521 of 5 stars$22.31-1.9%$80.33+260.1%+35.8%$416.60MN/A-3.05120News CoverageEarnings ReportUpcoming EarningsGap DownKODKodiak Sciences2.4201 of 5 stars$7.80-5.3%$9.00+15.4%+251.9%$411.56MN/A-2.1590Upcoming EarningsFULCFulcrum Therapeutics2.4498 of 5 stars$7.59-2.8%$7.43-2.1%-17.9%$409.70M$80M-108.41100High Trading VolumeCMPSCOMPASS Pathways2.8027 of 5 stars$4.29-1.2%$17.00+296.3%-36.9%$401.38MN/A-2.16120News CoverageAnalyst RevisionGap Up Related Companies and Tools Related Companies GOSS Alternatives ERAS Alternatives CMPX Alternatives KMDA Alternatives PVLA Alternatives RGNX Alternatives TECX Alternatives KOD Alternatives FULC Alternatives CMPS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SKYE) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredAltucher: Trump’s Great Gain is startingNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredShocked one of my clients with thisTrump Schedules Controversial 'Market Reset' for September 30 Behind closed doors, the White House has orde...Altimetry | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Skye Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Skye Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SKYE Stock Alerts